Related by context. All words. (Click for frequent words.) 68 chronic hepatitis C 65 hepatitis C HCV 65 chronic HCV infection 63 Phenoptin 63 virus HCV infection 63 refractory gout 63 albinterferon alfa 2b 63 hepatitis C genotype 62 chronic hepatitis B. 62 chronic HCV 61 hyperuricemia 61 Amigal 61 ORENCIA ® 61 Chronic Idiopathic Constipation 61 treatment naïve genotype 60 pegylated interferon alfa 2a 60 forodesine 60 relapsed multiple myeloma 60 HCV infection 60 phenylketonuria PKU 60 HCV 60 leukemia AML 60 systemic lupus erythematosus SLE 60 HCV genotype 1 60 onychomycosis 60 chronic hepatitis B 60 cIAI 60 interferon alfa 59 CCR5 tropic HIV 59 pegylated interferon alpha 59 FOLOTYN 59 chronic HBV 59 Hepatitis C virus HCV 59 LymphoStat B 59 TMC# [001] 59 toenail onychomycosis 59 nitazoxanide 59 pancreatic NET 59 treatment naive genotype 59 mRCC 59 HCV infected 58 peginterferon alfa 2a 58 OncoVEX GM CSF 58 chronic HBV infection 58 post herpetic neuralgia PHN 58 SHPT 58 advanced NSCLC 58 hepatocellular cancer 58 naïve HCV 58 HCV SPRINT 58 hypoparathyroidism 58 metastatic renal cell carcinoma 58 relapsed refractory multiple myeloma 58 hepatitis B HBV 58 BARACLUDE R 58 leukemia CLL 58 Clevudine 58 HCV genotypes 58 chronic ITP patients 58 PRTX 58 chronically infected 57 autoantibody positive 57 adult chronic ITP 57 relapsing multiple sclerosis 57 refractory chronic lymphocytic 57 telbivudine 57 ZALBIN 57 HBeAg negative 57 hepatitis C virus HCV 57 NOXAFIL 57 vandetanib 57 Pegasys ® 57 SNT-MC#/idebenone 57 HCV infections 57 registrational trial 57 NOMID 57 symptomatic BPH 57 Diabetic Macular Edema 57 CABP 57 cell lymphoma CTCL 57 Chronic hepatitis C 57 castrate resistant prostate cancer 57 refractory APL 57 HGS ETR1 57 cutaneous T cell 57 sorafenib tablets 57 BENLYSTA TM 57 SPRYCEL ® 57 HuMax CD4 56 INCB# [001] 56 Ophena TM 56 Chronic Hepatitis C 56 oral ridaforolimus 56 carcinoid syndrome 56 null responder HCV 56 Clostridium difficile associated 56 invasive aspergillosis 56 pancreatic neuroendocrine tumors 56 BARACLUDE ® 56 relapsing remitting multiple sclerosis 56 Albuferon 56 IBS C 56 Copegus ® ribavirin 56 non metastatic osteosarcoma 56 mixed dyslipidemia 56 chronic myeloid leukemia CML 56 chronic ITP 56 relapsing remitting MS 56 Acute Myeloid Leukemia AML 56 RDEA# 56 genital HSV 56 systemic juvenile idiopathic 56 null responder 56 Locteron 56 invasive candidiasis 56 candidemia 56 Sebivo 56 Dacogen injection 56 bendamustine 56 Zerenex 56 primary hypercholesterolemia 56 FOLOTYN ® 56 medullary thyroid cancer 56 terlipressin 56 CTAP# Capsules 55 PREZISTA r 55 oropharyngeal candidiasis OPC 55 chronic HCV genotype 55 Phase 2b trial 55 nosocomial pneumonia 55 refractory multiple myeloma 55 RhuDex ® 55 PEG PAL 55 peginterferon alfa 55 pegylated interferons 55 PEGINTRON TM 55 diabetic macular edema DME 55 post herpetic neuralgia 55 TYZEKA 55 CDAD 55 peginterferon alfa 2a Pegasys 55 protease inhibitor PI 55 forodesine hydrochloride 55 Recombinant interferon alpha 55 CCR5 tropic 55 refractory CLL 55 diabetic neuropathic pain 55 Bronchiectasis 55 celgosivir 55 Phase 2b study 55 dasatinib Sprycel ® 55 Nexavar ® 55 atypical Hemolytic Uremic Syndrome 55 STELARA 55 phase IIb study 55 Chronic HCV infection 55 virus HCV protease inhibitor 55 phase IIb clinical 55 lomitapide 55 Ilaris 55 thymalfasin 55 alfa 2a 55 SCH # 55 LEUKINE 55 ACTEMRA TM 55 pegylated interferon alfa 55 Phase Ib 55 ribavirin RBV 55 peginterferon 55 INC# 55 metastatic hormone refractory 55 Phase 2b clinical 55 Peginterferon alfa 2a 55 perifosine 55 ONGLYZA 55 opioid induced constipation OIC 55 VPRIV 55 AA amyloidosis 55 Altastaph 55 pivotal Phase III 55 posterior uveitis 55 refractory Hodgkin lymphoma 55 HspE7 55 Ceflatonin R 55 non alcoholic steatohepatitis 55 MPS VI 55 fidaxomicin 55 zidovudine AZT 55 LTBI 55 investigational compound 55 leukemia ALL 55 TYGACIL 55 Reverset 55 Primary IGFD 55 doripenem 55 HCV genotype 55 ISENTRESS 55 eosinophilic asthma 55 PEG INTRON R 55 latent TB infection 55 hepatocellular carcinoma 55 idiopathic pulmonary fibrosis IPF 55 HoFH 55 gastrointestinal stromal tumor GIST 55 hypertriglyceridemia 55 relapsing remitting MS RRMS 55 efalizumab 55 antiretroviral agents 55 CCR5 mAb 54 severe hypercholesterolemia 54 pralatrexate 54 TBC# 54 TREANDA 54 multicenter Phase III 54 AEG# 54 chronic plaque psoriasis 54 Myelodysplastic syndromes MDS 54 castration resistant prostate cancer 54 heterozygous FH 54 Severe Primary IGFD 54 lamivudine 54 recurrent genital herpes 54 HER2 positive metastatic breast 54 virus HCV 54 Fabry Disease 54 INCB# [002] 54 chronic lymphocytic leukemia CLL 54 lamivudine refractory patients 54 Sprycel dasatinib 54 Chronic lymphocytic leukemia 54 naive HCV 54 cutaneous T 54 Peg IFN 54 ALN TTR 54 Xyfid TM 54 TACI Ig 54 Jevtana 54 EDEMA3 54 Pegasys plus Copegus 54 QAB# 54 Tindamax R 54 TORISEL 54 talactoferrin 54 posaconazole 54 APTIVUS 54 Chronic Hepatitis B 54 RG# [001] 54 CAELYX 54 opioid induced constipation 54 relapsing forms 54 Plicera 54 Clolar 54 CEQ# 54 evaluating tivozanib 54 inhibitor RG# 54 SJIA 54 CRVO 54 T#I mutation 54 primary immunodeficiency PI 54 CCR5 antagonist 54 peginterferon alfa 2b 54 ceftazidime 54 hepatocellular carcinoma HCC 54 prostate cancer HRPC 54 neurogenic orthostatic hypotension 54 ADHF 54 ABSSSI 54 Omacetaxine 54 Arcalyst 54 postherpetic neuralgia 54 relapsing MS 54 Raptiva ® 54 pegylated interferon 54 e antigen HBeAg 54 dimebon 54 metastatic colorectal cancer 54 ketolide antibiotic 54 Rilonacept 54 oral deforolimus 54 mCRC 54 Peginterferon alfa 2b 54 Copegus ribavirin 54 diabetic nephropathy 54 HEPLISAV 54 ZYBRESTAT 54 MAGE A3 ASCI 54 alvimopan 54 Pegasys peginterferon alfa 2a 54 HeFH 54 placebo controlled Phase 54 blinatumomab 54 PEG interferon 54 Viramidine 54 Adalimumab 54 refractory AML 54 elotuzumab 54 lumiliximab 54 S. aureus infections 54 overactive bladder syndrome 54 metastatic renal cell 54 chronic myeloid 54 refractory chronic myeloid 54 partial onset seizures 54 relapsed MM 54 PNP inhibitor 54 Cetrorelix 54 non nucleoside inhibitor 54 doxorubicin HCl liposome injection 54 indolent NHL 54 dacarbazine 54 REMICADE ® 54 atypical antipsychotic medication 54 Raptiva R 54 HBeAg negative patients 54 Gemzar ® 54 sorafenib Nexavar ® 54 biologic therapy 53 interferon gamma 1b 53 lymphoma CTCL 53 PEGylated interferon beta 1a 53 Copegus ® 53 Severe Sepsis 53 certolizumab 53 phase IIa clinical 53 hormone refractory prostate cancer 53 BENLYSTA 53 decitabine 53 BCX# 53 Phase IIIb clinical 53 canakinumab 53 Idiopathic Pulmonary Fibrosis IPF 53 tamibarotene 53 recurrent glioma 53 telaprevir 53 Evoltra ® 53 Alinia 53 JANUVIA 53 Tamibarotene 53 BRIM2 53 Phase IIa clinical 53 Psoriasis affects 53 Pegasys R 53 Myelodysplastic Syndrome MDS 53 Pegylated Interferon 53 tivozanib 53 hyperphenylalaninemia HPA due 53 tanespimycin 53 Aflibercept 53 overactive bladder OAB 53 iclaprim 53 hepatitis B virus HBV 53 Ofatumumab 53 CANCIDAS 53 systemic fungal infections 53 systemic lupus erythematosus 53 STELARA TM 53 acute myelogenous leukemia AML 53 Aryplase 53 FLT3 mutations 53 acute PAO 53 LUX Lung 53 APTIVUS r 53 huC# DM4 53 metastatic castrate resistant 53 Sudhir Agrawal D.Phil 53 LymphoStat B belimumab 53 Corlux 53 Copegus 53 decompensated liver disease 53 Bronchitol 53 Traficet EN 53 diabetic macular edema 53 Irinotecan 53 Engerix B 53 acetonide FA 53 Phase IIb trials 53 Clolar ® 53 CIMZIA TM certolizumab pegol 53 genotype 1b 53 Randomized Phase 53 infections cIAI 53 heavily pretreated 53 Phase 1b clinical 53 severe plaque psoriasis 53 Copegus R 53 ONTAK 53 GW# [003] 53 Boceprevir 53 elevated triglyceride levels 53 Ribavirin 53 basiliximab 53 bacterial vaginosis BV 53 BEXXAR 53 rilonacept 53 systemic lupus 53 relapsed leukemia 53 plus gemcitabine 53 recurrent glioblastoma multiforme 53 esophageal candidiasis 53 GATTEX ® 53 orphan medicinal product 53 adalimumab 53 viral kinetics 53 HBeAg positive 53 Voreloxin 53 relapsed refractory AML 53 oral vancomycin 53 stage IIIB 53 COPEGUS ribavirin 53 Anturol 53 HBeAg positive patients 53 refractory metastatic colorectal cancer 53 Azilect ® 53 plus COPEGUS 53 metformin HCl 53 Yervoy 53 PD LID 53 PEG Interferon lambda 53 late onset Pompe 53 Fludara 53 oral mucositis 53 B CLL 53 antibody MAb 53 sunitinib 53 Cladribine Tablets 53 VFEND 53 Peginterferon 53 subcutaneous formulation 53 erlotinib Tarceva ® 53 achieve sustained virologic 53 ESRD patients 53 pediatric acute lymphoblastic 53 HCV protease inhibitor 53 pancreatic insufficiency 53 BAY #-# 53 Rheumatoid Arthritis RA 53 Sanofi Pasteur Fluzone 53 ribavirin therapy 53 Bezielle 53 achieved sustained virologic 53 velafermin 53 abatacept 53 acute myeloid leukemia AML 53 depression TRD 53 multicenter Phase 53 arthritis PsA 53 raltegravir 53 Daclizumab 53 ribavirin Copegus 53 valopicitabine 53 RRMS patients 53 registrational 53 acne vulgaris 53 Glufosfamide 53 GALNS 53 micafungin 53 eltrombopag 52 IMGN# 52 rheumatoid arthritis psoriatic arthritis 52 Phase Ib IIa 52 Viread tenofovir disoproxil fumarate 52 non nucleoside reverse 52 INVANZ 52 pediatric Crohn disease 52 Staphylococcus aureus infections 52 hereditary antithrombin deficiency 52 6R BH4 52 myelodysplastic myeloproliferative diseases 52 mipomersen 52 Civacir 52 vWD 52 INTELENCE 52 azacitidine 52 Lupus Nephritis 52 Tyzeka 52 Quinamed 52 Phase 1b 52 DermaVir Patch 52 orBec R 52 plus dexamethasone 52 CMV disease 52 acute leukemias 52 mcg albinterferon alfa 2b 52 Torisel 52 Phase 2a trial 52 myelodysplastic syndromes MDS 52 phase IIb trial 52 peginterferon alpha 2a 52 homozygous familial hypercholesterolemia 52 tenofovir disoproxil fumarate 52 plus ribavirin 52 acyclovir Lauriad R 52 Neovascular Age Related Macular 52 FASLODEX 52 MDR tuberculosis 52 latent tuberculosis infection 52 Advanced Melanoma 52 Phase 2a clinical 52 advanced hepatocellular carcinoma 52 lupus nephritis 52 Familial Adenomatous Polyposis FAP 52 Allovectin 7 R 52 ritonavir boosted atazanavir 52 postmenopausal osteoporotic women 52 diagnosed Ph + 52 vidofludimus 52 CoFactor 52 Pirfenidone 52 reslizumab 52 KRAS mutations occur 52 EOquin 52 IRESSA 52 ATTR 52 subcutaneously administered 52 Fx #A 52 Kit CD# positive 52 ACTEMRA 52 nucleotide analogue 52 Pegylated interferon 52 DOXIL 52 Major Depressive Disorder 52 non splenectomized 52 metastatic GIST 52 transcriptase inhibitor NNRTI 52 trastuzumab DM1 T DM1 52 Zalbin 52 ritonavir boosted 52 Hepatitis C HCV 52 JAK inhibitor 52 leukemia APL 52 PegIntron 52 lubiprostone 52 recurrent GBM 52 purpura ITP 52 dosing cohorts 52 MT# MEDI 52 chlorambucil 52 PEG INTRON 52 Increlex R 52 Genz # 52 metastatic melanoma 52 VELCADE melphalan 52 ocrelizumab 52 maraviroc 52 RSD# oral 52 SCIg 52 Golimumab 52 myelofibrosis 52 familial hypercholesterolemia 52 Cushing Syndrome 52 herpes zoster 52 Pulmonary Arterial Hypertension 52 Amrubicin 52 metastatic RCC 52 PANVAC VF 52 remission induction 52 chronic idiopathic constipation 52 visilizumab 52 gemcitabine chemotherapy 52 Morquio 52 acute decompensated heart 52 randomized Phase 52 follicular lymphoma FL 52 simplex virus 52 sunitinib malate 52 sargramostim 52 Alocrest 52 chemotherapy induced neutropenia 52 prGCD 52 SPRYCEL 52 cilengitide 52 ARIXTRA R 52 MyVax R 52 dose escalation study 52 PROSTVAC VF 52 CIMZIA 52 cirrhosis liver failure 52 VaD 52 mCRC patients 52 BCG refractory carcinoma 52 Phase Ib clinical 52 recurrent NSCLC 52 H#N# monovalent vaccine 52 Follicular Lymphoma 52 Naive Patients 52 alemtuzumab treated 52 metastatic colorectal carcinoma 52 TYKERB 52 Chlamydia trachomatis 52 chronic hepatitis 52 amoxicillin clavulanate 52 Maribavir 52 vinorelbine 52 Chronic Lymphocytic Leukemia CLL 52 Evoltra TM 52 Pegintron 52 dirucotide 52 ChronVac C R 52 double blinded placebo 52 biologic DMARD 52 elagolix 52 recurrent glioblastoma 52 plaque psoriasis 52 daclizumab 52 blinded randomized placebo controlled 52 Hepatocellular Carcinoma HCC 52 Ceflatonin 52 juvenile idiopathic arthritis JIA 52 dose intramuscular 52 Heterozygous Familial Hypercholesterolemia 52 telaprevir VX 52 low dose cytarabine 52 telaprevir dosed 52 pegylated interferon alpha 2a 52 KRN# 52 atherothrombotic events 52 NVA# 52 IDX# 52 herpes zoster shingles 52 Dapagliflozin 52 de novo kidney transplant 52 evaluating REVLIMID 52 VivaGel TM 52 Metastatic Colorectal Cancer 52 tenofovir emtricitabine 52 interferon alpha 52 QVA# 52 Zolinza 52 naive HCV genotype 52 gastrointestinal stromal tumors GIST 52 monotherapy 52 Menveo 52 Azixa 52 lesinurad 52 dose escalation clinical 52 Leukine 52 bevirimat 52 postherpetic neuralgia PHN 52 ofatumumab 52 metformin sulfonylurea 52 refractory NSCLC 52 Velcade bortezomib 52 REVLIMID ® 52 oral methylnaltrexone 52 CR# vcMMAE 52 tigecycline 52 Cethromycin 52 GATTEX ™ 52 chronic angina 52 latent TB 52 selective modulator 52 REVLIMID lenalidomide 52 AEGR 52 LymphoStat B TM 52 metastatic carcinoid 52 HIV coinfected 51 ZYVOX 51 StemEx R 51 superficial bladder cancer 51 vilazodone 51 Amplimexon 51 liprotamase 51 Peginterferon Alfa 2a 51 haematologic malignancies 51 Severe VOD 51 ocular hypertension 51 severe renal impairment 51 advanced metastatic renal 51 entecavir 51 Fludara ® 51 hepatitis C virus 51 Noxafil 51 refractory PTCL 51 chronic immune thrombocytopenic 51 unresectable stage 51 Egrifta 51 ZADAXIN 51 Hepsera 51 Dalbavancin 51 Prodarsan ® 51 PREZISTA 51 immunocompromised patients 51 Vertex telaprevir 51 hematological cancers 51 metastatic CRC 51 daptomycin 51 docetaxel chemotherapy 51 AAT deficiency 51 CMV infection 51 MAA submission 51 Twinrix 51 MKC# MT 51 acute ischemic stroke 51 CIMZIA TM 51 ceftaroline 51 Phase 1b trial 51 generation purine nucleoside 51 severe Primary IGFD 51 OPAXIO 51 Benign Prostatic Hyperplasia BPH 51 SEBIVO 51 tocilizumab 51 Cimzia TM 51 ISIS # 51 pulmonary hypertension PH 51 ZIAGEN 51 progressive PsA 51 nucleotide analog 51 uncomplicated influenza 51 velaglucerase alfa 51 AIR CF1 51 Clostridium difficile infection 51 interferon alfa 2b 51 Aptivus 51 fingolimod 51 PROMACTA 51 pomalidomide 51 KNS # 51 oral prodrug 51 Malignant Melanoma 51 achieved sustained virological 51 Infected Patients 51 pan HDAC inhibitor 51 AA Amyloidosis 51 PS# [001] 51 rilpivirine 51 XYOTAX TM 51 HuLuc# 51 Actimmune ® 51 liver transplantations 51 romidepsin 51 peg interferon 51 recurrent ovarian cancer 51 AAT Deficiency 51 trabectedin 51 CCR5 receptor antagonist 51 NUVIGIL 51 ponatinib 51 alpha 2b 51 Vectibix 51 OHR/AVR# 51 rALLy clinical trial 51 bevacizumab Avastin ® 51 HCV RESPOND 2 51 stage IIIB IV 51 AmBisome 51 trastuzumab Herceptin R 51 radezolid 51 dasatinib Sprycel 51 INSPIRE Trial Phase III 51 Actemra tocilizumab 51 ribavirin 51 ROTATEQ 51 ara C 51 palifosfamide 51 8mg/kg 51 Hepsera adefovir dipivoxil 51 Cimzia ® certolizumab pegol 51 Hepatitis C Virus HCV 51 OvaRex ® MAb 51 Renal Cell Carcinoma RCC 51 standard chemotherapy regimen 51 BRIM3 51 Proleukin 51 CTCL 51 lupus renal disease 51 thiazolides 51 voreloxin 51 virologic failure 51 Telbivudine 51 Phase IIa trial 51 ganetespib 51 NeuroStar TMS Therapy 51 L BLP# 51 Hodgkin lymphoma HL 51 Triapine 51 refractory acute myeloid 51 efavirenz emtricitabine 51 acute bacterial sinusitis 51 Tasigna nilotinib 51 tinidazole 51 carcinoid tumors 51 hematological malignancies 51 alvespimycin 51 Chronic Fatigue Syndrome CFS 51 postoperative ileus 51 phase IIa 51 mildly symptomatic 51 Phase III clinical 51 Phase Ib II 51 Myelofibrosis 51 thetreatment 51 hepatorenal syndrome 51 Phase #/#a trial 51 Laquinimod 51 AGILECT R 51 protease inhibitor telaprevir 51 VIDAZA 51 familial amyloidotic polyneuropathy FAP 51 sorafenib Nexavar 51 Diamyd ® 51 Systemic Sclerosis 51 Troxatyl 51 subependymal giant cell 51 novel VDA molecule 51 glucocorticoid induced osteoporosis 51 octreotide implant 51 oritavancin 51 rFIXFc 51 PEGINTRON 51 natalizumab 51 combination antiretroviral therapy 51 aztreonam 51 SIMPONI 51 Amgen Neulasta R 51 Taxotere ® 51 NSCLC 51 cariprazine 51 carfilzomib 51 Tipranavir 51 RSV infections 51 ELACYT 51 sodium glucose cotransporter 51 REBETOL combination therapy 51 mcg dose 51 discontinued Viread 51 Tygacil 51 cSSSIs 51 elvucitabine 51 Ozarelix 51 evaluable subjects 51 oral FTY# 51 functional dyspepsia 51 MAXY alpha 51 glufosfamide 51 placebo controlled Phase III 51 abacavir Ziagen 51 Genasense ® 51 dose cohort 51 CCX# B 51 octreotide 51 prokinetic agent 51 Hepatitis C Virus 51 unresectable recurrent 51 T2DM 51 ACZ# 51 PEGASYS ® 51 Navelbine ® 51 rituximab refractory 51 omalizumab 51 CIMZIA ™ 51 Nexavar sorafenib 51 multiple myeloma MM 51 myelodysplastic syndromes 51 Restanza 51 QNEXA 51 Annamycin 51 T Pred 51 G#D mutation 51 Irritable Bowel Syndrome IBS 51 Allovectin 7 51 anti TNF alpha 51 Allovectin 7 ® 51 Mipomersen 51 hematologic malignancies 51 cetuximab Erbitux ® 51 Aptivus ® 51 DORIBAX 51 Chronic Myeloid Leukemia 51 boosted protease inhibitor 51 Incivek 50 BCR ABL inhibitors 50 romiplostim 50 Telintra 50 IRX 2 50 Nitazoxanide 50 lintuzumab SGN 50 MEK inhibitor 50 fostamatinib 50 Picoplatin 50 poor metabolizers 50 Hodgkin lymphoma NHL 50 Vaccine Recombinant 50 BR.# 50 eculizumab 50 Acute Bacterial Skin 50 Telaprevir 50 Vandetanib 50 zanolimumab 50 HQK 50 latent tuberculosis 50 polymerase inhibitor 50 abacavir lamivudine 50 genotype 1a 50 galiximab 50 oxypurinol 50 Vidaza azacitidine 50 Phase IIb trial 50 interferon alfa 2a 50 telavancin 50 S. aureus bacteremia 50 REBETOL 50 #mg QD [002] 50 metaglidasen 50 KRAS mutant tumors 50 Bortezomib 50 CD3 monoclonal antibody 50 ankylosing spondylitis AS 50 BCR ABL inhibitor 50 indinavir Crixivan 50 PREZISTA ritonavir 50 lapatinib Tykerb 50 Perifosine 50 calcineurin inhibitors 50 etravirine 50 Newly Diagnosed Multiple Myeloma 50 clevudine 50 nucleoside naive 50 HCV Protease Inhibitor 50 Myocet 50 multicenter Phase II 50 coinfected 50 Human papilloma virus 50 darapladib 50 fallopian tube carcinoma 50 REMUNE R 50 HCD# [002] 50 relapsed AML 50 Cutaneous T 50 adalimumab Humira 50 GSK# [001] 50 mg QD 50 generation NNRTI 50 dirucotide MBP# 50 FOLFOX 50 teduglutide 50 nucleoside analog 50 Lambert Eaton Myasthenic 50 omega interferon 50 macroalbuminuria 50 nasopharyngeal cancer 50 pexiganan 50 MYDICAR ® 50 invasive fungal infections 50 YONDELIS 50 AzaSite Plus 50 Eculizumab 50 histone deacetylase HDAC inhibitor 50 lixisenatide 50 IV Busulfex 50 regorafenib 50 sJIA 50 cancer cachexia 50 XmAb# 50 Canvaxin 50 chronic granulomatous disease 50 Firazyr 50 TASKi2 50 lenalidomide Revlimid R 50 Afinitor 50 HCV Genotype 50 disease CDAD 50 PEG IFN 50 vicriviroc 50 XL# [003] 50 lorvotuzumab mertansine 50 saxagliptin 50 uncomplicated malaria 50 amphotericin B 50 pegfilgrastim 50 Sustiva efavirenz 50 L MTP PE 50 hypercalcemia 50 NXL# 50 Clofarabine 50 steroid refractory ulcerative 50 Valopicitabine 50 Arzerra ofatumumab 50 Tanespimycin 50 maribavir 50 controlled dose escalation 50 SNT MC# 50 malignant gliomas 50 Lupus nephritis 50 multiple ascending dose 50 sustained virological response 50 NATRECOR R 50 R5 tropic 50 mapatumumab 50 allergic asthma 50 pramlintide 50 SUTENT 50 ARCOXIA 50 denufosol 50 belinostat 50 PegIFN RBV 50 REYATAZ ® 50 fibromyalgia syndrome 50 Lymphocytic